Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers
Background: Inactivated vaccine (CoronaVac) and chimpanzee adenovirus-vector vaccine (ChAdOx1) have been widely used in resource-limited settings. However, the information on the reactogenicity and immunogenicity of these two vaccines in the same setting are limited. Methods: Healthy health care wor...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | Vaccine: X |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136222000134 |
| _version_ | 1818644857300713472 |
|---|---|
| author | Nasikarn Angkasekwinai Jaturong Sewatanon Suvimol Niyomnaitham Supaporn Phumiamorn Kasama Sukapirom Sompong Sapsutthipas Rujipas Sirijatuphat Orasri Wittawatmongkol Sansnee Senawong Surakameth Mahasirimongkol Sakalin Trisiriwanich Kulkanya Chokephaibulkit |
| author_facet | Nasikarn Angkasekwinai Jaturong Sewatanon Suvimol Niyomnaitham Supaporn Phumiamorn Kasama Sukapirom Sompong Sapsutthipas Rujipas Sirijatuphat Orasri Wittawatmongkol Sansnee Senawong Surakameth Mahasirimongkol Sakalin Trisiriwanich Kulkanya Chokephaibulkit |
| author_sort | Nasikarn Angkasekwinai |
| collection | DOAJ |
| description | Background: Inactivated vaccine (CoronaVac) and chimpanzee adenovirus-vector vaccine (ChAdOx1) have been widely used in resource-limited settings. However, the information on the reactogenicity and immunogenicity of these two vaccines in the same setting are limited. Methods: Healthy health care workers (HCWs) aged 18 years or older were randomly assigned to receive either two doses of CoronaVac at 4 weeks interval or two doses of ChAdOx1 at 10 weeks interval. Self-reported adverse events (AEs) were collected for 7 days following each vaccination. Immunogenicity was determined by IgG antibodies levels against receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S1 subunit) and the 50% plaque reduction neutralization titers against various strains. Results: Of the 360 HCWs, 180 in each vaccine group, the median (interquartile range: IQR) age was 35 (29–44) years old and 84.2% were female. Participants who received ChAdOx1 reported higher frequency of AEs than those received CoronaVac after both the first dose (84.4% vs. 66.1%, P < 0.001) and second dose (75.6% vs. 60.6%, P = 0.002), with more AEs in those younger than 30 years of age for both vaccines. The seroconversion rates were 75.6% and 100% following the first dose of CoronaVac and ChAdOx1, respectively. All participants were seropositive at 2 weeks after the second dose. The anti-SARS-CoV-2 RBD IgG levels induced by CoronaVac was lower than ChAdOX1 with geometric means of 164.4 and 278.5 BAU/mL, respectively (P = 0.0066). Both vaccines induced similar levels of neutralizing antibodies against the Wuhan strain, with the titers of 337.4 and 331.2; however, CoronaVac induced significantly lower GMT against Alpha (23.1 vs. 92.5), Delta (21.2 vs. 69.7), and Beta (10.2 vs. 43.6) variants, respectively. Conclusion: CoronaVac induces lower measurable antibodies against circulating variants but with lower frequency of AEs than ChAdOx1. An earlier boosting to prevent breakthrough infections may be needed. |
| first_indexed | 2024-12-17T00:21:31Z |
| format | Article |
| id | doaj.art-3c35a05b20af4615be50ab5732a280fa |
| institution | Directory Open Access Journal |
| issn | 2590-1362 |
| language | English |
| last_indexed | 2024-12-17T00:21:31Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Vaccine: X |
| spelling | doaj.art-3c35a05b20af4615be50ab5732a280fa2022-12-21T22:10:33ZengElsevierVaccine: X2590-13622022-04-0110100153Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workersNasikarn Angkasekwinai0Jaturong Sewatanon1Suvimol Niyomnaitham2Supaporn Phumiamorn3Kasama Sukapirom4Sompong Sapsutthipas5Rujipas Sirijatuphat6Orasri Wittawatmongkol7Sansnee Senawong8Surakameth Mahasirimongkol9Sakalin Trisiriwanich10Kulkanya Chokephaibulkit11Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, ThailandDepartment of Microbiology, Faculty of Medicine Siriraj Hospital, Mahidol University, ThailandDepartment of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; Siriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj Hospital, Mahidol University, ThailandDepartment of Medical Sciences, Ministry of Public Health, ThailandBiomedical Research Incubator Unit, Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; Siriraj Center of Research Excellence in Microparticle and Exosome in Disease, ThailandDepartment of Medical Sciences, Ministry of Public Health, ThailandDepartment of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, ThailandDepartment of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, ThailandDepartment of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, ThailandDepartment of Medical Sciences, Ministry of Public Health, ThailandDepartment of Medical Sciences, Ministry of Public Health, ThailandSiriraj Institute of Clinical Research (SICRES), Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; Corresponding author at: Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Siriraj Institute of Clinical Research (SICRES), 2 Wanglang Road, Bangkoknoi, Bangkok 10700, Thailand.Background: Inactivated vaccine (CoronaVac) and chimpanzee adenovirus-vector vaccine (ChAdOx1) have been widely used in resource-limited settings. However, the information on the reactogenicity and immunogenicity of these two vaccines in the same setting are limited. Methods: Healthy health care workers (HCWs) aged 18 years or older were randomly assigned to receive either two doses of CoronaVac at 4 weeks interval or two doses of ChAdOx1 at 10 weeks interval. Self-reported adverse events (AEs) were collected for 7 days following each vaccination. Immunogenicity was determined by IgG antibodies levels against receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S1 subunit) and the 50% plaque reduction neutralization titers against various strains. Results: Of the 360 HCWs, 180 in each vaccine group, the median (interquartile range: IQR) age was 35 (29–44) years old and 84.2% were female. Participants who received ChAdOx1 reported higher frequency of AEs than those received CoronaVac after both the first dose (84.4% vs. 66.1%, P < 0.001) and second dose (75.6% vs. 60.6%, P = 0.002), with more AEs in those younger than 30 years of age for both vaccines. The seroconversion rates were 75.6% and 100% following the first dose of CoronaVac and ChAdOx1, respectively. All participants were seropositive at 2 weeks after the second dose. The anti-SARS-CoV-2 RBD IgG levels induced by CoronaVac was lower than ChAdOX1 with geometric means of 164.4 and 278.5 BAU/mL, respectively (P = 0.0066). Both vaccines induced similar levels of neutralizing antibodies against the Wuhan strain, with the titers of 337.4 and 331.2; however, CoronaVac induced significantly lower GMT against Alpha (23.1 vs. 92.5), Delta (21.2 vs. 69.7), and Beta (10.2 vs. 43.6) variants, respectively. Conclusion: CoronaVac induces lower measurable antibodies against circulating variants but with lower frequency of AEs than ChAdOx1. An earlier boosting to prevent breakthrough infections may be needed.http://www.sciencedirect.com/science/article/pii/S2590136222000134CoronVacChAdOx1Heath care workersThailandImmunogenicityVariant of concern |
| spellingShingle | Nasikarn Angkasekwinai Jaturong Sewatanon Suvimol Niyomnaitham Supaporn Phumiamorn Kasama Sukapirom Sompong Sapsutthipas Rujipas Sirijatuphat Orasri Wittawatmongkol Sansnee Senawong Surakameth Mahasirimongkol Sakalin Trisiriwanich Kulkanya Chokephaibulkit Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers Vaccine: X CoronVac ChAdOx1 Heath care workers Thailand Immunogenicity Variant of concern |
| title | Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers |
| title_full | Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers |
| title_fullStr | Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers |
| title_full_unstemmed | Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers |
| title_short | Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers |
| title_sort | comparison of safety and immunogenicity of coronavac and chadox1 against the sars cov 2 circulating variants of concern alpha delta beta in thai healthcare workers |
| topic | CoronVac ChAdOx1 Heath care workers Thailand Immunogenicity Variant of concern |
| url | http://www.sciencedirect.com/science/article/pii/S2590136222000134 |
| work_keys_str_mv | AT nasikarnangkasekwinai comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers AT jaturongsewatanon comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers AT suvimolniyomnaitham comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers AT supapornphumiamorn comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers AT kasamasukapirom comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers AT sompongsapsutthipas comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers AT rujipassirijatuphat comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers AT orasriwittawatmongkol comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers AT sansneesenawong comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers AT surakamethmahasirimongkol comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers AT sakalintrisiriwanich comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers AT kulkanyachokephaibulkit comparisonofsafetyandimmunogenicityofcoronavacandchadox1againstthesarscov2circulatingvariantsofconcernalphadeltabetainthaihealthcareworkers |